These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847 [TBL] [Abstract][Full Text] [Related]
67. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913 [TBL] [Abstract][Full Text] [Related]
68. Total and free plasma neuroleptic levels in schizophrenic patients. Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586 [TBL] [Abstract][Full Text] [Related]
69. Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. Altamura AC; Tacchini GL; Maes M Eur Neuropsychopharmacol; 1995; 5 Suppl():55-8. PubMed ID: 8775759 [TBL] [Abstract][Full Text] [Related]
70. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. Yasui N; Kondo T; Otani K; Furukori H; Mihara K; Suzuki A; Kaneko S; Inoue Y J Clin Psychopharmacol; 1999 Apr; 19(2):149-54. PubMed ID: 10211916 [TBL] [Abstract][Full Text] [Related]
71. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. Meyer JM CNS Spectr; 2014 Oct; 19(5):432-8. PubMed ID: 24865765 [TBL] [Abstract][Full Text] [Related]
72. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Yao JK; van Kammen DP Schizophr Res; 1994 Feb; 11(3):209-16. PubMed ID: 8193060 [TBL] [Abstract][Full Text] [Related]
73. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients. Kim YH; Cha IJ; Shim JC; Shin JG; Yoon YR; Kim YK; Kim JI; Park GH; Jang IJ; Woo JI; Shin SG J Clin Psychopharmacol; 1996 Jun; 16(3):247-52. PubMed ID: 8784658 [TBL] [Abstract][Full Text] [Related]
74. Haloperidol plasma concentrations in Taiwanese psychiatric patients. Lane HY; Lin HN; Hwu HG; Jann M; Hu WH; Chang WH J Formos Med Assoc; 1995 Nov; 94(11):671-8. PubMed ID: 8527974 [TBL] [Abstract][Full Text] [Related]
75. Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients. Chang WH; Hwu HG; Lane HY; Lin SK; Chen TY; Chen H; Wei HL; Lin WL; Lin HN Psychiatry Res; 1991 Sep; 38(3):215-25. PubMed ID: 1754634 [TBL] [Abstract][Full Text] [Related]
76. Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication. Libiger J; Czobor P; Volavka J Psychiatry Res; 1994 May; 52(2):107-14. PubMed ID: 7972567 [TBL] [Abstract][Full Text] [Related]